MK-2866, commonly known as Ostarine, is a selective androgen receptor modulator (SARM) that has been investigated for its potential to affect muscle and bone tissue. It is distinct from anabolic steroids in its proposed mechanism of action, aiming to selectively target androgen receptors in certain tissues while minimizing effects on other organs. Although often discussed in contexts related to muscle enhancement, MK-2866 is not approved for medical use in humans by the U.S. Food and Drug Administration (FDA) or other major regulatory bodies. It has primarily been studied in preclinical and clinical research settings, often for conditions involving muscle wasting or bone loss. The sublingual form refers to its administration method, where the liquid is absorbed under the tongue. (Source: PubChem, FDA Website).
Deep dive
Tap a section to expand.
Known interactions
Category rule: peptide × hormone
Note
Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.
Track bloodwork with a provider; don't assume combinations are neutral.
Frequently asked
Sources referenced
["PubChem","DrugBank","NIH National Library of Medicine (PubMed)","U.S. Food and Drug Administration (FDA) Website","NIH ClinicalTrials.gov","Cochrane Library Reviews","U.S. Anti-Doping Agency (USADA)"]
Stackwise compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician.
Related compounds
Others in the hormone category or studied for the same goals.